相关实验视频

Updated: Jun 18, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在老年鼻癌中,基于洛巴普拉丁的并发化疗和放射治疗

Yi-Feng Yu¹, Ping Zhou¹, Rui Zhou¹

¹Department of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.

Annals of medicine

|August 1, 2024

概括

基于洛巴的并发化疗放射治疗 (CCRT) 在老年鼻癌 (NPC) 患者中显示出有希望的疗效和可控的毒性. 这种治疗为这个人群提供了有利的短期生存结果.

科学领域:

在瘤学瘤学.
放射疗法是一种放射治疗.
医学瘤学医学瘤学

背景情况:

在老年鼻癌 (NPC) 患者中,同时进行化疗放射治疗 (CCRT) 的益处受到争议.
在老年NPC患者中研究基于洛巴的CCRT的疗效和毒性至关重要.

研究的目的:

在老年NPC患者 (≥65岁) 中评估基于洛巴的CCRT的疗效和安全性.
评估客观的反应率,生存结果和与治疗相关的毒性.

主要方法:

对29名老年NPC患者 (II期-IVA) 进行了回顾性研究,这些患者接受了洛巴普拉丁和强度调节辐射疗法 (IMRT) 治疗.
分析了客观反应率,毒性概况 (血液学,粘膜炎) 和生存率 (卡普兰-梅尔).

主要成果:

观察到高的整体响应率 (92.0%治疗前,100%治疗后).
最常见的毒性是血液性 (白血病,中性病,血小板减少);3级粘膜炎发生在34.5%的人中.
没有肝脏或脏功能障碍;3年生存率很高 (局部无复发95.8%,无远程转移85.7%,无进展82.5%,总体100%).

结论:

基于洛巴普拉丁的CCRT是老年NPC患者的安全和可行的选择.
治疗表明了令人满意的短期存活率和可接受的毒性概况.
目前正在进行第二阶段试验,以进一步评估长期结果和毒性.

关键词:

鼻癌是指鼻癌.洛巴金金是什么意思辐射疗法辐射疗法幸存率幸存率生存率治疗对治疗的反应反应.

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...